Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.